James D Campbell
Affiliation: Centers for Disease Control and Prevention
- HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrheaJames D Campbell
Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Entebbe, Uganda
Clin Infect Dis 54:1204-11. 2012..Many countries recommend that individuals taking antiretroviral therapy (ART) discontinue cotrimoxazole when CD4 counts are >200 cells/μL. However, this practice has not been evaluated in sub-Saharan Africa...
- Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adultsJames D Campbell
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
Hum Vaccin 7:81-8. 2011..In conclusion, the newly-licensed vaccine was well tolerated and immunologically non-inferior to the established vaccine for all three vaccine strains in the whole population and the elderly...
- Hematologic changes associated with Zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural UgandaFatu Forna
Global AIDS Program, National Center for HIV, Hepatitis, STD, and TB Prevention NCHHSTP, CDC, Atlanta, Georgia, USA
J Int Assoc Physicians AIDS Care (Chic) 8:128-38. 2009..The authors evaluated hematologic changes associated with zidovudine (ZDV) following single-drug substitution from stavudine (D4T) in HIV-infected persons in Uganda...
- Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trialPamela M Murnane
aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
AIDS 27:2155-60. 2013..One hypothesis proposed for these divergent results is that PrEP efficacy may be reduced in populations with higher HIV-1 incidence...
- Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIVJames D Campbell
Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda
Am J Prev Med 44:S63-9. 2013..PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted...
- Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injectorJakub K Simon
Division of Geomedicine, Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, United States
Vaccine 29:9544-50. 2011..In the first study in humans, the newly-US-licensed LectraJet(®) model M3 RA DSJI was compared to N-S...